Dupilumab reduces COPD exacerbations and Type 2 inflammation biomarkers, with strongest benefit in patients with high ...

Merck MRK announced a definitive agreement to acquire Verona Pharma VRNA for approximately $10 billion. The deal will add ...

Objectives The association between smoking and patients with schizophrenia has been established through epidemiological ...

Increasing prevalence of COPD and other respiratory illnesses across hospitals and home care settings is driving the demand ...

This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ...

The CAAT governance board recommends transitioning from the COPD Assessment Test to the CAAT and using it for patients with ...

Dr. Maria Munoz-Bramhall discusses her journey from nursing to family medicine, focusing on pulmonary care, pediatric ...

Verona Pharma plc (NASDAQ:VRNA) is one of the 10 Stocks Going Wild. Verona Pharma surged by 20.62 percent on Wednesday to end ...

Both nicotine cravings and levels of cotinine significantly fell in adults treated with cytisinicline vs. placebo who failed ...

Merck & Co. has agreed to acquire Verona Pharma for $10 billion, the companies said, in a deal designed to expand the pharma ...

Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive pulmonary disease. While Ohtuvayre is projected to become a blockbuster product ...

The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.